List of Diagnostics Companies in France - 30

Acobiom is specialized in the identification of new Biomarkers and in the development of innovative Diagnostics in Translational Research and Precision Medicine. The company provides also customized services in genomics, transcriptomics, bioinformatics and biostatistics (data science), thanks to its technology platform and its scientific expertise. For more information about Acobiom, please contact the company by email: busdev@acobiom.com, or visit its website: www.acobiom.com.

To be more responsive, more efficient and make better decisions, BforCure allows public and industrial stakeholders to access biological information in real time, thanks to an innovative technology of rapid biodetection.

bioMérieux develops in vitro products to diagnose infectious diseases, cancer and cardiovascular disease and to detect microorganisms in agri-foods, pharmaceuticals and cosmetics.BioFire COVID-19 test

Créée en 2005 et basée à Strasbourg en Alsace, la société BIOSYNEX conçoit, fabrique et distribue des Tests de Diagnostic Rapide (TDR). Dans leur version professionnelle, ils offrent une meilleure prise en charge médicale des patients grâce à la rapidité de leur résultat et à leur simplicité d'utilisation. Dans leur version autotest, ils permettent au grand public une autosurveillance de diverses pathologies assurant ainsi une meilleure prévention et accélérant la demande de soins. Leader sur le marché des TDR en France, BIOSYNEX est le seul acteur à maîtriser intégralement sa chaîne de valeur grâce à sa plateforme technologique déclinable sur de nombreuses applications et adaptée à différents types d'utilisateurs tels les laboratoires, les hôpitaux, les médecins et le grand public. Acteur majeur de la santé publique avec 140 collaborateurs et une gamme de 1700 références en France dont notamment le test Exactop du dépistage du HIV, BIOSYNEX a reçu en novembre 2017 les prix de l'Innovation dans la catégorie Biotech & Science de la vie et le prix de la société cotée Euronext au palmarès national du Deloitte In Extenso Technology Fast 50. Plus d'informations sur www.BIOSYNEX.com BIOSYNEX was founded in 2005 and is one of the most significant European manufacturers and provider of rapid membrane tests in the in-vitro diagnostic market. By staying close to our customers and business partners we are aware of the needs and expectations they may have of our products and services. Listening to their voice, together with the help of our Research and Development laboratories in France and our state of the art manufacturing facilities, allows us to identify new applications in rapid testing, develop and launch innovative products and provide high quality services. Our aim is to provide innovative diagnostic tests to help physicians make fast and better medical and therefore lifesaving decisions.

Curium is the global leader in nuclear medicine, providing life-changing diagnostics and treatment to patients all over the world. We develop, manufacture and distribute world-class radiopharmaceutical products with a renewed focus on cancer, exploring untapped potential for new innovation. We build on remarkable foundations and a legacy of providing reliable and consistent nuclear solutions to tens of thousands of patients every day. Our proven heritage combined with a pioneering approach are the hallmarks from which we provide life-changing diagnostics and therapeutics. Our people are the root of the incredible impact they have. As part of our 2030 vision to become an oncology-focused nuclear medicine leader – both in diagnostics and therapy – we will expand our reach further into Japan and China, continuing to roll out our superior products to a global market. The impact of these investments on patients will be life changing. Our cancer focus is currently in Neuroendocrine Tumors (NETs) and prostate cancer PSMA. We are also working on leveraging the power of AI to improve image quality and accuracy; to identify patterns to help diagnose pathologies and of course to better support physicians. Our Promise We strive to make the impossible possible and to be an organization that will change the face of medicine. Our diverse group of industry experts is unified under one strong and singular focus – to develop, manufacture and supply revolutionary diagnostic and therapeutic radiopharmaceuticals to our customers around the globe with unrivaled reliability and superior service.

We are a clinical stage biopharmaceutical company developing developing breakthrough immunomodulatory drugs for the treatment of cancer and inflammatory diseases. We have developed two highly promising pipelines of clinical and pre-clinical candidates with a focus on cancer and auto-immune diseases: - OncoMimics™: highly effective, off-the-shelf therapeutic vaccines against cancers (EO2401, EO2463). EO2401 is in Phase 1/2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463 is in a Phase 1/2 clinical trial for indolent non-Hodgkin B-cell lymphomas. - EndoMimics™: a pipeline of next generation bioactives acting like human hormones or cytokines for the treatment of immune diseases. EB1010, the lead candidate, is a potent local inducer of IL-10 designed to provide improved therapeutic outcomes for patients with IBD. In addition, Enterome’s clinical candidate sibofimloc (also referred to as TAK-018) is advancing through a Phase 2 clinical trial in post-operative Crohn’s disease. Sibofimloc has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.

Le groupe Eurobio Scientific est un acteur intégré français du diagnostic in vitro. Aujourd'hui, leader sur le marché français du diagnostic in-vitro, le groupe Eurobio Scientific poursuit son développement en intervenant de la recherche à la commercialisation de produits diagnostiques de spécialités et de produits dans le domaine des sciences de la vie. Le savoir-faire d'Eurobio Scientific repose sur la commercialisation de tests de diagnostic de spécialité auprès des laboratoires d'analyses de biologie médicale hospitaliers et privés. Le groupe est également reconnu en France comme étant le leader du marché des tests HLA pour la transplantation. Eurobio Scientific commercialise également en exclusivité des tests et des solutions automatisées conçus par nos partenaires industriels étrangers (américains, coréens, européens…) dans les domaines des maladies infectieuses, de l'auto-immunité et des contrôles qualité. Une offre de qualité : - Une gamme de réactifs et d'instruments dédiés aux laboratoires des sciences de la vie. - Fabrication de ses produits propriétaires en interne, dans l'unité de production implantée dans les locaux de son siège, dans une salle blanche de plus de 400 m² permettant la fabrication d'unité stérile. Production de qualité, appréciée des clients d'Eurobio. Un portefeuille étendu et diversifié de produits propriétaires dans quatre spécialités : la transplantation, les maladies infectieuses, les sciences du vivant et le cancer.

GENCLIS SA is a privately-held French Biotechnology that discovered a unique biological mechanism referred as to Transcription Infidelity (TI). Transcription Infidelity is a newly discovered and patented mechanism that incresases RNA-DNA sequence divergences (RDD). TI can lead to base substitutions, insertions and deletions. The latter cause translational frameshifts that have important consequences in determining protein immunogenicity. Genclis currently focuses on defining the effects of TI proteins translated from gapped RNA on normal and pathological humoral immunity.

At Guerbet, we build lasting relationships so that we enable people to live better. This is our Purpose. We place human cooperation at the heart of our relationships and actions. We are a leader in medical imaging worldwide, offering a wide range of pharmaceutical products, medical devices, digital and AI solutions for diagnostic and interventional imaging. A pioneer since 95 years in the field of contrast media, we are a team of over 2,600 people globally, continuously innovating with 10% of revenue dedicated to Research & Development across four centers in France, Israel and the United States.

HalioDx utilizes a proprietary set of Immune biomarkers, advanced image analysis technologies and a unique know-how to develop, manufacture and commercialize immune-based diagnostics services and products.

Ikonisys is a cell based diagnostics company, that markets the proprietary Ikoniscope® Digital Microscope, designed to deliver highly accurate and reliable detection of rare cells. Utilizing advanced molecular and immunological markers, Ikoniscope-built applications are extensively used in the US and Europe for the diagnosis of a variety of cancers.

Immusmol develops small molecule antibodies for research, diagnostics and therapy. Combining 25 years of experience in antigen design, we offer to target low molecular weight molecules, which are not usually addressed by antibodies, such as amino acid metabolites, lipids, saccharids, toxins, pesticide residues, small molecule drugs, ... Compatible with existing antibody-based technologies, our small molecule antibodies can serve for: > VISUALIZATION: Small molecule antibodies currently represent the only applicable technology for the visualization of small molecules in cells and tissues by IF or IHC. > QUANTIFICATION: Combined with ELISA/EIA technologies, small molecule antibodies enable rapid and robust detection of small molecules in biological samples (an attractive alternative to mass-spec and aptamer-based technologies). > MODULATION: Small molecules represent a vast class of neglected drug targets. ImmuSmol is currently developing a pipeline of proprietary monoclonal antibodies interfering with endogenous small molecules involved in cancer and CNS disorders.

IntegraGen is an OncoDNA group company specializing in the genomics of cancer and rare genetic diseases. Backed by highly competent and qualified teams, IntegraGen is a leading player in DNA sequencing services and genomic data interpretation software. The company runs one of the largest NGS labs in France and operates for research institutes of excellence. As part of OncoDNA group, IntegraGen leverages the power of next generation sequencing with the mission of delivering the promise of precision medicine to patients. IntegraGen has about 50 employees and generated €9 million of revenue in 2020. Based in France, IntegraGen is also present in the United States and is part of the OncoDNA group which works with an international network of 35 distributors. The Group also provides biomarker testing and clinical interpretation tools to guide treatment and monitoring of late stage solid tumors and accelerate the development of new cancer drugs. IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 - Mnemo: ALINT - Eligible PEA-PME).

KOELIS has assisted urologists and radiologists from around the world in their routine clinical practice since 2006, providing the latest technology for personalized prostate cancer planning and management, from biopsy to active surveillance and treatment. Focused on developing advanced, targeted and less invasive solutions, KOELIS is committed to creating and bringing to the market a new paradigm in prostate cancer care, where physicians can offer the most personalized answers to their patients, avoiding any under or overtreatment and preserving quality of life. Thanks to cutting-edge imaging tools like Trinity® cartographer, which combines multiple imaging modalities with full 3D ultrasound, any suspicious lesion is characterized in a detailed 3D prostate map, offering a comprehensive and multiparametric approach and enhancing diagnostic confidence. The team at KOELIS innovates every day in collaboration with world-renowned universities and hospitals to offer physicians new advancements in imaging and a greater field of view, a must-have in active surveillance and targeted treatment. Based in Grenoble and Princeton, KOELIS technology has been featured in more than 50 clinical publications and treats more than 300,000 patients worldwide, including patients in Europe, United States, Canada, Japan, Australia, South America and the Middle East.

Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and eyonis™, our AI/ML tech-based suite of software as medical devices (SaMD) help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world. Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label "Innovative company" by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME).

At Metafora, we develop innovative and impactful AI-powered cytometry & cell metabolism profiling solutions. We are passionate about cell biology. We leverage our unique cell metabolism and AI-powered data analysis platforms to turn disruptive single-cell technologies into impactful solutions that improve human health.

MSInsight, a French health-tech company, empowers the fight against cancer by revealing actionable information from the genome. We are committed to developing a portfolio of state-of-the-art diagnostic solutions for Microsatellite Instability (MSI) status. MSI has been shown to be an indicator of treatment response, especially for immune checkpoint inhibitors, and as an important pan-cancer biomarker. We aim to propose bioinformatic tools for delivering insights on microsatellite mutational variations using Next-Generation Sequencing (NGS) data. Our flagship product, MSIcare, will be available as a robust diagnostic, prognostic, and theranostic assistant for guiding clinical decision-making.

At Novacyt, we pride ourselves on concentrating our expertise on specific market needs. Offering a comprehensive and developing portfolio of quality products, backed by proven supply and delivery services, to ensure the highest possible standards of customer service around the world. Our passion is for customer-centric solutions that advance the science behind diagnostics. This fuels our drive to deliver products that save lives and help in the fight against infectious disease. We offer an increasing portfolio of in-vitro diagnostic tests, utilising molecular and protein detection technologies – supporting healthcare and disease prevention across the globe in the clinical and life science sectors. Deep strengths in product development, commercialisation, contract design, and manufacturing ensure quality products and robust supply. Our Group has specialist experience and expertise throughout our business units: Primerdesign, Microgen Bioproducts, IT-IS international, and Lab21 Healthcare – creating solutions for the diagnostics industry, supplying an extensive range of high-quality assays and reagents worldwide.

We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity

Orakl Oncology leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With our platform we partner with oncology players to identify relevant targets and deliver new drugs, faster.

PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection.The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurance managers/production managers.

Qynapse is a neuroimaging technology company founded in 2015, originating from the CATI consortium of neuroimaging research laboratories. Based in France, with offices in the U.S. and Canada, Qynapse is dedicated to enhancing the diagnosis and monitoring of central nervous system (CNS) disorders, including Alzheimer’s disease, Multiple Sclerosis, and Parkinson’s disease. The company focuses on improving accuracy and reliability in clinical and research environments through AI-driven solutions. Qynapse offers proprietary AI-powered tools for analyzing neuroimaging data, such as MRI and PET scans. Its key product, QyScore®, features an automated platform with 20 algorithms and over 200 measures for assessing neurodegeneration and neuroinflammation. The company also provides clinical trial solutions that significantly reduce image-reading variability, enhancing trial efficiency, and normative datasets that deliver precise imaging metrics for tracking disease progression. Qynapse serves pharmaceutical and biotech companies, healthcare providers, and researchers, aiming to improve patient outcomes and accelerate drug development timelines.

Build the first Radiological Foundation Model Bring the radiological image to GPT Share the world's top medical expertise through AI Bring the best specialist to every patient/researcher/company

Spotlight Medical is a precision medicine company striving to free all patients from cancer through a better understanding of each patient’s unique disease. We develop advanced AI tests that enhance treatment selection by leveraging decades of patient data. This ensures personalized and effective care for each individual, significantly improving patient outcomes and quality of life. By closely collaborating with physicians, we create impactful tests that address critical unmet clinical needs, opening a new era in cancer care. Founded in 2024, Spotlight Medical is backed by Institut Curie and Gustave Roussy, and has raised more than 6 million Euros to implement its first AI-driven test in clinical routine set to be announced soon.

Created in 1945 as a pharmaceutical company, Diagnostica Stago is now a world leader in the In-Vitro Diagnostics industry. Global, privately-owned and independent, Stago is fully dedicated to the exploration of Thrombosis and Haemostasis. Day in and day out, Stago is committed to enhancing the quality of healthcare by offering laboratories advanced testing systems and superior services, the fruit of our expertise and know-how in Haemostasis (reagents, instruments and disposables). Distributed in over 110 countries through a network of subsidiaries and exclusive distributors, we are in a position to guarantee our customers superior service and a product portfolio meeting the demands of global healthcare systems. Today, 90% of our production, developed and made in France, is exported. Specialising in the field of coagulation for over 60 years, Stago has acquired solid industrial experience (R&D, standardisation and production) in the field of In Vitro Diagnostics and lasting recognition from the scientific community. The field of biomedical science is constantly evolving and expanding; new discoveries are moving medicine increasingly towards individual treatments that require diagnostic markers and ever more precise exploratory tools. These are our challenges of tomorrow. Stago, relying on strong human and technological potential, will still have much to contribute in the years to come.

Stallergenes Greer is a global biopharmaceutical company specialising in the diagnosis and treatment of respiratory, food allergies and venoms through the research, development and commercialisation of allergen immunotherapy products and services. Our purpose is to enable precision medicine to improve life for people with allergies. With nearly 1,100 employees worldwide, a presence in 44 countries, and manufacturing facilities in both Europe and the United States, Stallergenes Greer International AG is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France). With complementary strengths, joint heritage and reputations, Stallergenes Greer is driving a continuing leadership in allergy immunotherapy. Link to our privacy policy: https://www.stallergenesgreer.com/personal-data-protection-policy

Surgimab SAS is a biotechnology company based out of Montpellier, Languedoc-Roussillon, France.

Therapixel is a leading french software company specialized in artificial intelligence for medical imaging. Our aim is to develop a digital radiologist achieving the performance of best experts. Our AI is dedicated to breast cancer screening. That algorithm won the Digital Mammography DREAM Challenge, the largest Artificial Intelligence challenge ever organized. In its early years, Therapixel developed images visualization software for surgeons to make image access easier and faster from patient consultation to the operating room thanks to gesture control and intuitive user interfaces.

Volta Medical leverages artificial intelligence to revolutionize interventional cardiac electrophysiology. Its cutting-edge software solutions use machine and deep learning algorithms to assist operators during cardiac ablation procedures. Volta's DNA is to provide physicians with solutions that are user-friendly. Its first medical device, VX1, consists of a cue-giving interface designed to facilitate the identification of abnormal electrograms during ablation of complex arrhythmias such as atrial fibrillation. With VX1, operators keep their go-to navigation system and catheters. The VX1 real-time analysis algorithm has been trained on carefully curated databases of annotated intra-cardiac electrograms. The solution may be used as a support to assist electrogram-based atrial fibrillation ablation. VX1 is CE marked and FDA cleared. VX1 was the first artificial intelligence-based software solution to be FDA cleared in the interventional cardiology space. Volta Medical is expanding at a fast rate across the globe. Multiple partnerships have been formed with leading centers in Europe and the US.

Ziwig ® is a French company whose ambition is to improve women’s health through a holistic approach and the development of products, services and a care ecosystem guided by science and the unique biology of each individual. This approach is supported by ongoing research excellence and is based on the close collaboration of medical experts and engineers specialized in cutting- edge technologies such as artificial intelligence and Next Generation human RNA Sequencing. Its functioning is based on an ecosystem, driven by the quest for excellence and patient centered, that uses disruptive technologies. This contributes to the emergence of precision medicine that is individualized, predictive and participatory, serving women’s well-being and quality of life. Ziwig’s work has resulted in several publications that have appeared in international peer-reviewed scientific journals such as diagnostics, Nature scientific reports and Journal of Clinical Medicine. Follow us on Instagram : https://www.instagram.com/ziwigfrance/